Abstract: The present disclosure relates in some aspects to chimeric signaling receptors containing an extracellular domain capable of binding a molecule, such as an immunosuppressive cytokine, and a MyD88-containing intracellular domain capable of engaging a signaling pathway to activate an immune cell. In some aspects, the disclosure further relates to engineered cells, such as T cells, and compositions comprising the chimeric signaling receptors or engineered cells, and methods and uses thereof. In some embodiments, the cells may further express a genetically engineered recombinant antigen receptor directed against an antigen, such as a chimeric antigen receptor (CAR) or recombinant T cell receptor (TCR) and, in some cases, secrete a recombinant molecule, for example, a bispecific antibody.
Type:
Application
Filed:
July 16, 2021
Publication date:
October 5, 2023
Applicants:
Simurx, Inc., Children's Hospital Los Angeles
Inventors:
Shahab ASGHARZADEH, Babak MOGHIMI, Michael HADJIDANIEL, Soheila SHIRINBAK